US Vaccine Technologies Marke Overview
The US vaccine technologies market is experiencing significant growth, driven by advancements in biotechnology, increasing demand for immunization, and heightened awareness of public health. US Predictive Disease Analytics Market Industry is expected to grow from 896(USD Million) in 2024 to 8,903.42 (USD Million) by 2035. The US Predictive Disease Analytics Market CAGR (growth rate) is expected to be around 23.214% during the forecast period (2025 - 2035).
Market Overview
The US vaccine market is characterized by a diverse range of technologies, including mRNA, recombinant, conjugate, viral vector, live attenuated, inactivated, and toxoid vaccines. The success of mRNA vaccines, particularly during the COVID-19 pandemic, has accelerated research and development in this area, leading to the exploration of mRNA platforms for other infectious diseases such as influenza and RSV . Additionally, the integration of artificial intelligence (AI) in vaccine development is enhancing the efficiency of regulatory processes, demand forecasting, and personalized vaccine design .
Key Market Segments
The market is segmented based on technology, disease indication, end-user, and delivery method. Recombinant, conjugate, and subunit vaccines hold a significant share due to their high efficacy and safety profiles. These vaccines are particularly effective in immunizing against bacterial infections like Haemophilus influenzae type B and Streptococcus pneumoniae . Viral vector vaccines are also gaining prominence for their ability to induce strong immune responses without the need for adjuvants .
In terms of disease indication, vaccines targeting pneumococcal disease, influenza, HPV, meningococcal disease, and hepatitis are among the most in demand. The end-user segment is divided into pediatric, adult, and traveler populations, with pediatric vaccines accounting for a substantial portion due to routine immunization programs . Regarding delivery methods, parenteral administration remains dominant, but oral vaccines are expected to witness significant growth due to their non-invasive nature and ease of administration .
Industry Latest News
Recent developments in the US vaccine market include Moderna's study on a combination mRNA flu and COVID-19 vaccine, which showed a stronger immune response in individuals aged 50 and older compared to existing standalone vaccines. However, the FDA has requested more direct evidence of the vaccine’s effectiveness in preventing illness and hospitalization before approval . Additionally, Novavax is in ongoing discussions with the FDA regarding the full approval of its COVID-19 vaccine, with expectations of resolving regulatory concerns soon .
In the regulatory landscape, the appointment of Dr. Vinay Prasad as the FDA’s top vaccine regulator has stirred discussions due to his critical stance on pharmaceutical industry practices and COVID-19 public health measures . Furthermore, GSK and Pfizer have settled a global patent dispute over their respective RSV vaccines, Arexvy and Abrysvo, with Pfizer agreeing to pay royalties to GSK.
Key Companies
The US vaccine technologies market comprises several key players, including Pfizer, Moderna, Merck & Co., GSK, Sanofi, Novavax, and emerging biotech firms like Vaxart and Agenus. Pfizer and Moderna have been at the forefront of mRNA vaccine development, while Merck & Co. and GSK continue to lead in recombinant and conjugate vaccine technologies . Vaxart is notable for its development of oral recombinant vaccines in tablet form, aiming to improve vaccine accessibility and compliance . Agenus contributes to the market with its QS-21 Stimulon adjuvant platform, enhancing immune responses in various vaccines .
Several factors are propelling the growth of the US vaccine technologies market. The increasing prevalence of infectious diseases, coupled with heightened public awareness and government initiatives promoting immunization, is driving demand. Technological advancements, particularly in mRNA and recombinant vaccine platforms, are enabling faster and more efficient vaccine development. The integration of AI and bioinformatics is facilitating personalized vaccine design and improving supply chain management . Additionally, favorable reimbursement policies and funding from governmental and non-governmental organizations are supporting research and development efforts .
Regional Insights
Within the United States, vaccine technology adoption varies by region, influenced by factors such as population density, healthcare infrastructure, and public health policies. Urban areas with robust healthcare systems, such as those in California, New York, and Massachusetts, are leading in vaccine research and implementation. The southern and midwestern regions are also witnessing growth, supported by federal grants and private investments aimed at enhancing healthcare access and digitalization. Furthermore, initiatives to expand telemedicine and cross-state data-sharing are facilitating the broader reach of vaccine technologies to underserved populations .
Explore MRFR’s Related Ongoing Coverage In Healthcare Domain:
Comments
0 comment